Breaking News

Financial Report: Astra Zeneca

April 26, 2012

Revenues drop 11%

Astra Zeneca

1Q Revenues: $7.3 billion (-11%)

1Q Earnings: $1.6 billion (-43%)

Comments: Loss of exclusivity on several key brands, mainly Seroquel IR, Nexium and Arimidex, accounted for 8% of revenue decline, which included a $223.0 million returns reserve against US trade inventories of Seroquel IR. Restructuring costs were $702.0 million in the quarter. U.S. revenues were down 12% impacted by generic competition. Revenue in the Rest of World was down 11%, with revenue declines in Brazil, Turkey and Mexico accounting for more than 40% of the shortfall. R&D expense increased 2% in the quarter.
blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success